Bank of America Corp DE Has $63.19 Million Stock Position in United Therapeutics Co. (NASDAQ:UTHR)

Bank of America Corp DE increased its stake in United Therapeutics Co. (NASDAQ:UTHR - Free Report) by 6.7% during the 4th quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The fund owned 179,077 shares of the biotechnology company's stock after purchasing an additional 11,246 shares during the period. Bank of America Corp DE owned 0.40% of United Therapeutics worth $63,186,000 at the end of the most recent reporting period.

Other hedge funds have also made changes to their positions in the company. Parallel Advisors LLC raised its position in United Therapeutics by 2.8% during the fourth quarter. Parallel Advisors LLC now owns 1,090 shares of the biotechnology company's stock valued at $385,000 after buying an additional 30 shares during the period. Signaturefd LLC raised its position in United Therapeutics by 4.7% during the fourth quarter. Signaturefd LLC now owns 663 shares of the biotechnology company's stock valued at $234,000 after buying an additional 30 shares during the period. Anchor Investment Management LLC raised its position in United Therapeutics by 12.0% during the fourth quarter. Anchor Investment Management LLC now owns 280 shares of the biotechnology company's stock valued at $99,000 after buying an additional 30 shares during the period. Great Lakes Advisors LLC raised its position in United Therapeutics by 1.6% during the fourth quarter. Great Lakes Advisors LLC now owns 1,974 shares of the biotechnology company's stock valued at $697,000 after buying an additional 31 shares during the period. Finally, Oregon Public Employees Retirement Fund raised its position in United Therapeutics by 0.4% during the fourth quarter. Oregon Public Employees Retirement Fund now owns 9,108 shares of the biotechnology company's stock valued at $3,214,000 after buying an additional 33 shares during the period. Institutional investors own 94.08% of the company's stock.

United Therapeutics Stock Performance

Shares of UTHR traded up $4.24 during trading hours on Thursday, hitting $303.92. 486,726 shares of the company were exchanged, compared to its average volume of 442,352. The company has a market cap of $13.71 billion, a PE ratio of 13.35, a PEG ratio of 0.97 and a beta of 0.58. The firm's 50 day moving average is $300.21 and its 200-day moving average is $341.23. United Therapeutics Co. has a 52 week low of $264.33 and a 52 week high of $417.82.

United Therapeutics (NASDAQ:UTHR - Get Free Report) last released its quarterly earnings results on Wednesday, April 30th. The biotechnology company reported $6.63 earnings per share (EPS) for the quarter, topping the consensus estimate of $6.29 by $0.34. The company had revenue of $794.40 million during the quarter, compared to the consensus estimate of $726.82 million. United Therapeutics had a return on equity of 19.22% and a net margin of 40.31%. The firm's revenue was up 17.2% on a year-over-year basis. During the same quarter in the prior year, the company posted $6.17 EPS. As a group, equities analysts forecast that United Therapeutics Co. will post 24.48 earnings per share for the current fiscal year.

Wall Street Analysts Forecast Growth

UTHR has been the topic of several recent analyst reports. Morgan Stanley upped their price target on United Therapeutics from $346.00 to $348.00 and gave the company an "equal weight" rating in a research report on Thursday, May 1st. Wells Fargo & Company restated an "equal weight" rating and issued a $314.00 target price (down previously from $395.00) on shares of United Therapeutics in a research note on Friday, April 25th. StockNews.com downgraded United Therapeutics from a "strong-buy" rating to a "buy" rating in a research note on Friday, May 2nd. JPMorgan Chase & Co. lowered their target price on United Therapeutics from $355.00 to $350.00 and set an "overweight" rating on the stock in a research note on Thursday, May 1st. Finally, HC Wainwright restated a "buy" rating and issued a $425.00 target price on shares of United Therapeutics in a research note on Monday, May 5th. Four analysts have rated the stock with a hold rating and nine have given a buy rating to the company's stock. According to data from MarketBeat.com, United Therapeutics has an average rating of "Moderate Buy" and a consensus price target of $392.00.

Insider Buying and Selling

In related news, EVP Paul A. Mahon sold 11,000 shares of the business's stock in a transaction dated Thursday, April 3rd. The stock was sold at an average price of $306.18, for a total transaction of $3,367,980.00. Following the completion of the transaction, the executive vice president now owns 36,781 shares of the company's stock, valued at approximately $11,261,606.58. The trade was a 23.02% decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, Director Tommy G. Thompson sold 2,500 shares of the business's stock in a transaction dated Monday, March 24th. The stock was sold at an average price of $318.80, for a total value of $797,000.00. Following the transaction, the director now directly owns 8,480 shares of the company's stock, valued at $2,703,424. This represents a 22.77% decrease in their position. The disclosure for this sale can be found here. In the last 90 days, insiders sold 65,500 shares of company stock valued at $20,765,280. Insiders own 11.90% of the company's stock.

About United Therapeutics

United Therapeutics Corporation, a biotechnology company, engages in the development and commercialization of products to address the unmet medical needs of patients with chronic and life-threatening diseases in the United States and internationally. The company offers Tyvaso DPI, an inhaled dry powder via pre-filled and single-use cartridges; Tyvaso, an inhaled solution via ultrasonic nebulizer; Remodulin (treprostinil) injection to treat patients with pulmonary arterial hypertension (PAH) to diminish symptoms associated with exercise; Orenitram, a tablet dosage form of treprostinil, to delay disease progression and improve exercise capacity in PAH patients; and Adcirca, an oral PDE-5 inhibitor to enhance the exercise ability in PAH patients.